Showing results (261-270 of 322) with videos related to
Sort By:
Pageof 33
Scientific Reports|July 2, 2020
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2Jin Roh, Hyungwoo Cho, Dok Hyun Yoon, et al.American Journal of Hematology|January 11, 2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)Ho Sup Lee, Kihyun Kim, Seok Jin Kim, et al.Annals of Hematology|December 22, 2009
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancerJoon Oh Park, Sang-We Kim, Jin Seok Ahn, et al.Journal of Gastroenterology and Hepatology|December 12, 2013
Endoscopic and clinical analysis of primary T-cell lymphoma of the gastrointestinal tract according to pathological subtypeDo Hoon Kim, Danbi Lee, Jeong Won Kim, et al.American Journal of Hematology|June 15, 2007
Consideration of aggressive therapeutic strategies for primary testicular lymphomaByeong-Bae Park, Jong Gwang Kim, Sang Kyun Sohn, et al.Oncotarget|August 20, 2016
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)Dok Hyun Yoon, Seok Jin Kim, Seong Hyun Jeong, et al.European Journal of Cancer (Oxford, England : 1990)|July 10, 2012
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trialSeok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, et al.Annals of Hematology|July 27, 2011
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trialHye Jin Kim, Sung-Soo Yoon, Dong Soon Lee, et al.Annals of Hematology|September 17, 2011
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) studyHye Jin Kang, Won Seog Kim, Seok Jin Kim, et al.Pageof 33